Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5/2019

01-10-2019 | Peritoneal Cancer | Research Paper

Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

Authors: Álvaro Jesús Gómez-Ruiz, Alida González-Gil, José Gil, Álvaro Navarro-Barrios, Felipe Alconchel, Elena Gil, Jerónimo Martínez, Aníbal Nieto, Francisco Barceló, Pedro Antonio Cascales-Campos

Published in: Clinical & Experimental Metastasis | Issue 5/2019

Login to get access

Abstract

In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.
Appendix
Available only for authorised users
Literature
1.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259CrossRefPubMed
2.
Salani R, Bristow RE (2012) Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol 55: 75–95CrossRefPubMed
3.
Sugarbaker PH (2000) It’s what the surgeon doesn’t see that kills the patient. J Nippon Med Sch 67(1):5–8CrossRefPubMed
4.
Zang RY, Harter P, Chi DS et al (2011) Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 105(7):890–896CrossRefPubMedPubMedCentral
5.
Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112(1):265–274CrossRefPubMed
6.
Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol 13(12):1702–1710CrossRefPubMed
7.
Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289CrossRefPubMed
8.
Du Bois A, Vergote I, Ferron G et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. JCO 35(15_suppl):5501CrossRef
9.
Tian W-J, Chi DS, Sehouli J et al (2012) A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 19(2):597–604CrossRefPubMed
10.
Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575CrossRefPubMed
11.
12.
13.
Foster JM, Sleightholm R, Smith L et al (2016) Re: the American Society of peritoneal surface malignancies multi-institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: an introduction of the peritoneal surface disease severity score. J Surg Oncol 114(7):779–784 (Journal of Surgical Oncology. 2018;118(4):720–720)CrossRefPubMed
14.
Cascales-Campos P, López-López V, Gil J et al (2016) Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference? Surg Oncol 25(3):164–170CrossRefPubMed
15.
Cascales-Campos PA, Gil J, Feliciangeli E et al (2015) The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol 22(3):987–993CrossRefPubMed
16.
Cascales-Campos PA, Gil J, Gil E et al (2014) Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol 21(7):2383–2389CrossRefPubMed
17.
Cascales Campos P, Gil J, Parrilla P (2014) Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. Eur J Surg Oncol 40(8):970–975CrossRefPubMed
18.
19.
Rose PG, Nerenstone S, Brady MF et al (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351(24):2489–2497CrossRefPubMed
20.
Yarema R, Fetsych T, Volodko N, Оhorchak M, Petronchak O, Huley R et al (2018 Jun) Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: two pathogenetic types based study. J Surg Oncol 117(8):1806–1812CrossRefPubMed
21.
Iavazzo CR, Kopanakis ND, Spiliotis JD (2018 Sep) Hyperthermic intraperitoneal chemotherapy for ovarian cancer: peritoneal surface disease severity score-preliminary results. J Surg Oncol 118(3):591–592PubMed
22.
van de Laar R, Zusterzeel PL, Van Gorp T et al (2014) Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer 14(1):22CrossRefPubMedPubMedCentral
23.
Llueca A, Serra A, Rivadulla I, Gomez L, Escrig J, MUAPOS Working Group (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery) (2018) Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index. World J Surg Oncol 16(1):37CrossRefPubMedPubMedCentral
24.
Tentes A-AK, Tripsiannis G, Markakidis SK et al (2003) Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 29(1):69–73CrossRefPubMed
Metadata
Title
Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC
Authors
Álvaro Jesús Gómez-Ruiz
Alida González-Gil
José Gil
Álvaro Navarro-Barrios
Felipe Alconchel
Elena Gil
Jerónimo Martínez
Aníbal Nieto
Francisco Barceló
Pedro Antonio Cascales-Campos
Publication date
01-10-2019
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2019
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-019-09982-1

Other articles of this Issue 5/2019

Clinical & Experimental Metastasis 5/2019 Go to the issue

Research Paper

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

Research Paper

The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis

Research Paper

Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells

Research Paper

Factors related to the quality of life in patients with bone metastases

Research Paper

Quantification of PpIX-fluorescence of cerebral metastases: a pilot study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits